) The human prostate is androgen dependent and prostate cancer (CaP), maintains this dependence on androgens. CaP undergoes apoptosis and regression following androgen withdrawal but eventually recurs in the absence of testicular androgens. The human CaP xenograft (CWR22) propagated in male nude mice, retains these biological characteristics including regression following castration and recurrence of growth after several months in the absence of testicular androgen. Following the withdrawal of androgen stimulation, AR levels decrease in CWR22. However, recurrent CWR22 tumors express high levels of AR relative to the regressing CWR22 from castrated mice. In recurrent CWR22 the increased intensity of nuclear immunostaining is consistent with AR activation in the absence of androgen. Moreover, androgen-regulated mRNAs that decrease in CWR22 tumors following castration are up-regulated in the recurrent XWR22. The goal of this research is to establish the role of AR and the AR target gene network in the androgen-independent growth of CaP.
Specific Aims of this project are to: (1) Delineate the mechanisms controlling steady state expression levels of AR mRNA and protein in CWR 22 tumors after castration and recurrent growth. Characterize the activation properties of AR (protein stability and phosphorylation) in recurrent CWR22 tumors. (2) Identify androgen-regulated genes in CWR22 with emphasis on potential mediators of AR-stimulated cell growth. Compare the levels of expression of these androgen-regulated genes in CWR22 with emphasis on potential mediators of AR-stimulated cell growth. Compare the levels of expression of these androgen- regulated genes in castrate mice. (3) Determine the androgen-independent function of AR in the recurrent CWR22 tumors using a dominant- negative AR to inhibit AR to inhibit AR transactivation and an AR- directed ribozyme to prevent AR expression. (4) Elucidate the mechanism controlling expression of androgen-regulated genes in the recurrent CWR22 (a) AR-dependent mechanism; or (b) non-AR dependent mechanism.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA077739-05
Application #
6652760
Study Section
Project Start
2002-08-26
Project End
2003-07-31
Budget Start
Budget End
Support Year
5
Fiscal Year
2002
Total Cost
$208,271
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Li, Qiuhui; Deng, Qu; Chao, Hsueh-Ping et al. (2018) Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nat Commun 9:3600
Fiandalo, Michael V; Wilton, John H; Mantione, Krystin M et al. (2018) Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models. Prostate 78:213-221
Askew, Emily B; Bai, Suxia; Parris, Amanda B et al. (2017) Androgen receptor regulation by histone methyltransferase Suppressor of variegation 3-9 homolog 2 and Melanoma antigen-A11. Mol Cell Endocrinol 443:42-51
Komisarof, Justin; McCall, Matthew; Newman, Laurel et al. (2017) A four gene signature predictive of recurrent prostate cancer. Oncotarget 8:3430-3440
Su, Shifeng; Chen, Xiaoyu; Geng, Jiang et al. (2017) Melanoma antigen-A11 regulates substrate-specificity of Skp2-mediated protein degradation. Mol Cell Endocrinol 439:1-9
Itkonen, Harri M; Brown, Michael; Urbanucci, Alfonso et al. (2017) Lipid degradation promotes prostate cancer cell survival. Oncotarget 8:38264-38275
Stocking, John J; Fiandalo, Michael V; Pop, Elena A et al. (2016) Characterization of Prostate Cancer in a Functional Eunuch. J Natl Compr Canc Netw 14:1054-60
Frasinyuk, Mykhaylo S; Mrug, Galyna P; Bondarenko, Svitlana P et al. (2016) Antineoplastic Isoflavonoids Derived from Intermediate ortho-Quinone Methides Generated from Mannich Bases. ChemMedChem 11:600-11
Minges, John T; Grossman, Gail; Zhang, Ping et al. (2015) Post-translational Down-regulation of Melanoma Antigen-A11 (MAGE-A11) by Human p14-ARF Tumor Suppressor. J Biol Chem 290:25174-87
Montecinos, Viviana P; Morales, Claudio H; Fischer, Thomas H et al. (2015) Selective targeting of bioengineered platelets to prostate cancer vasculature: new paradigm for therapeutic modalities. J Cell Mol Med 19:1530-7

Showing the most recent 10 out of 103 publications